MedTrace Logo

A Study for Observing Severe Asthma in Patients Treated With Tezepelumab

NCT05677139 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 513

Last updated 2026-03-16

No results posted yet for this study

Summary

A study involving primary data collection within real-world settings of participants who initiate treatment with tezepelumab for severe uncontrolled asthma. This study will complement evidence obtained from randomized controlled trials and provide new data focusing on the holistic and patient reported outcome (PRO).

Conditions

Interventions

OTHER

None (Observational Study)

Not applicable since it's an observational study.

Sponsors & Collaborators

Eligibility

Min Age
12 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-13
Primary Completion
2026-02-27
Completion
2026-02-27

Countries

  • Austria
  • Belgium
  • Canada
  • Denmark
  • Germany
  • Israel
  • Italy
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05677139 on ClinicalTrials.gov